Reported Earlier, Praxis Announces 2025 Milestones: Advancing Relutrigine, Ulixacaltamide, And Rare Disease Programs With $470M In Cash Reserves

-0.68% Pre

PRAXIS PRECISION MEDICINES, INC.

PRAX

274.51

-0.68%

0.00% Pre

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028
Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1 2025 interim analysis; NDA filing for ulixacaltamide expected in 2025
Enrollment in EMBOLD study of relutrigine cohort 2 is on track; targeting NDA filing in 2026
Vormatrigine ENERGY program advancing with read-outs of RADIANT in first half of 2025 and POWER1 by year-end 2025
UCB has exercised its option to license KCNT1 small molecule candidate for global development and commercialization
Cash and investments ~ $470 million at the end of 2024 support runway into 2028

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.